行情

AMGN

AMGN

安进
NASDAQ

实时行情|Nasdaq Last Sale

205.41
-3.47
-1.66%
盘后: 203.72 -1.69 -0.82% 17:43 04/03 EDT
开盘
207.43
昨收
208.88
最高
209.75
最低
203.03
成交量
228.14万
成交额
--
52周最高
244.99
52周最低
166.30
市值
1,211.52亿
市盈率(TTM)
15.95
分时
5日
1月
3月
1年
5年

分析师评级

28位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AMGN价格均价为243.21,最高价位285.00,最低价为185.00。

EPS

AMGN 新闻

更多
  • Video: 4 Large-Cap Stocks With Strong Buffett-Munger Characteristics
  • GuruFocus.com · 6小时前
  • Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
  • Zacks · 14小时前
  • With gowns and masks in short supply, researchers test drugs to prevent COVID-19 infections in health care workers
  • MarketWatch · 15小时前
  • V&M Breakouts: Top Growth And Dividend Stocks For April 2020
  • Seeking Alpha - Article · 1天前

所属板块

制药
-0.14%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

AMGN 简况

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
展开

微牛提供Amgen, Inc.(NASDAQ-AMGN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AMGN股票新闻,以帮助您做出投资决策。